Patents
From foundational patents to delivery technology, we have pioneered the development of mRNA medicine since our founding. Along the way, we have accumulated a broad collection of patents, with several hundred additional pending patent applications.
Intellectual Property
The following articles are protected by the following United States patents for Moderna Inc.
Spikevax™ (mRNA-1273 COVID-19 VACCINE)
In addition, Moderna Inc. owns additional patents in the United States and foreign jurisdictions.